Quick Answer
CorMedix Inc. reported Cash and Equivalents of $144.84 million for fiscal year 2025.
CorMedix Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $144.84M | +256.3% |
| 2024 | $40.65M | -6.9% |
| 2023 | $43.64M | +1.1% |
| 2022 | $43.15M | -19.1% |
| 2021 | $53.32M | +27.2% |
| 2020 | $41.91M | +156.3% |
| 2019 | $16.35M | -7.2% |
| 2018 | $17.62M | +69.8% |
| 2017 | $10.38M | +28.7% |
| 2016 | $8.06M | -31.8% |
| 2015 | $11.82M | +172.3% |
| 2014 | $4.34M | +82.8% |
| 2013 | $2.37M | +184.1% |
| 2012 | $835.5K | -57.9% |
| 2011 | $1.99M | -76.0% |
| 2010 | $8.28M | +450.3% |
| 2009 | $1.51M | — |
| 2006 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $48.49M | +37.4% | -69.6% |
| June 30, 2025 | $159.31M | +458.2% | +140.3% |
| March 31, 2025 | $66.29M | +88.4% | +63.1% |
| December 31, 2024 | $40.65M | -6.9% | +15.2% |
| September 30, 2024 | $35.29M | -33.8% | +23.6% |
| June 30, 2024 | $28.54M | +44.9% | -18.9% |
| March 31, 2024 | $35.18M | +39.2% | -19.4% |
| December 31, 2023 | $43.64M | +1.1% | -18.1% |
- CorMedix Inc. showed an increase of +256.3% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from CorMedix Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: